# US 2026/0076924 A1 · Compositions and methods of treatment for tinea pedis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076924 A1
- Document ID: US20260076924A1
- Status: Published application
- Kind: A1
- Application number: 19/005,149
- Filed: 2024-12-30
- Published: 2026-03-19
- Earliest claimed: 2020-09-03
- Assignees: Therapeutics, Inc.
- Applicants: Therapeutics, Inc.
- Inventors: Walter THOMPSON
- Web page: https://patentgrep.com/patent/US20260076924A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61P 31/10: Antimycotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions containing a synergistic combination of at least one antifungal active ingredient and at least one keratolytic agent and methods of treating tinea pedis with the pharmaceutical compositions are described. These pharmaceutical compositions include synergistic combinations of naftifine or terbinafine and urea, or naftifine or terbinafine and ammonium lactate, for effective treatment of moccasin-type and interdigital-type tinea pedis.

## Claims

### Claim 1

A method for treating tinea pedis in a subject, the method comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, the composition comprising a synergistic combination of at least one antifungal active ingredient and at least one keratolytic agent,
wherein the at least one antifungal active ingredient is selected from the group consisting of pharmaceutically acceptable forms of terbinafine, butenafine, amorolfine, clotrimazole, econazole, ketoconazole, miconazole, tioconazole, fluconazole, itraconazole, posaconazole, voriconazole, a pharmaceutically acceptable salt thereof, and a combination thereof, and
wherein the at least one keratolytic agent is selected from the group consisting of urea, ammonium lactate, salicylic acid, podofilox, podophyllum resin, trichloroacetic acid, alpha-hydroxy acids, poly hydroxyl acids, lactic acid, allantoin, resorcinol, glycolic acid, and combinations thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition further comprises at least one additional excipient selected from the group consisting of at least one solvent, at least one emollient, at least one viscosity modifier, at least one humectant, at least one emulsifier, at least one penetration enhancer, and at least one pH modifier.

### Claim at position 3

-21. (canceled)

### Claim 22 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes miconazole, and wherein the at least one keratolytic agent includes urea.

### Claim 23 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes miconazole, and wherein the at least one keratolytic agent includes ammonium lactate.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes miconazole, and wherein the at least one keratolytic agent includes salicylic acid.

### Claim 25 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes tioconazole, and wherein the at least one keratolytic agent includes urea.

### Claim 26 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes tioconazole, and wherein the at least one keratolytic agent includes ammonium lactate.

### Claim 27 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes tioconazole, and wherein the at least one keratolytic agent includes salicylic acid.

### Claim 28 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes fluconazole, and wherein the at least one keratolytic agent includes urea.

### Claim 29 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes fluconazole, and wherein the at least one keratolytic agent includes ammonium lactate.

### Claim 30 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes fluconazole, and wherein the at least one keratolytic agent includes salicylic acid.

### Claim 31 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes butenafine, and wherein the at least one keratolytic agent includes urea.

### Claim 32 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes butenafine, and wherein the at least one keratolytic agent includes ammonium lactate.

### Claim 33 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes terbinafine, and wherein the at least one keratolytic agent includes urea.

### Claim 34 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes terbinafine, and wherein the at least one keratolytic agent includes ammonium lactate.

### Claim 35 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes clotrimazole, and wherein the at least one keratolytic agent includes urea.

### Claim 36 (depends on 1)

The method according to claim 1, wherein the at least one antifungal active ingredient includes clotrimazole, and wherein the at least one keratolytic agent includes ammonium lactate.

### Claim 37 (depends on 1)

The method of claim 1, wherein the subject is being treated once daily for moccasin-type tinea pedis or for interdigital-type tinea pedis.

### Claim 38 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered once or twice daily for at least two weeks for moccasin-type tinea pedis.

### Claim 39 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises about 1.3% by weight of the at least one antifungal active ingredient and about 30% by weight of the keratolytic agent.
